Sign in
4

Changes in Ownership

Processa Pharmaceuticals, Inc. Filed Acc 0001567619-23-000324

Options or other derivatives

  • Chief Financial Officer acquired 178,768 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Stanker James H Chief Financial Officer 2022-12-31 Grant or award · Restricted Stock Units −12,951 352,614 D
Stanker James H Chief Financial Officer 2023-01-01 Grant or award · Restricted Stock Units −69,667 422,281 D
Stanker James H Chief Financial Officer 2023-01-01 Grant or award · Restricted Stock Units −96,150 518,431 D
Loading xslF345X03/doc1.xml…